RxDoctor Payments Data

Clifford Salinger, MD

Ophthalmology · Palm Beach Gardens, FLNPI 1891888418

Payments from drug & device makers

$162,814in general payments, 2019–2025

Across 387 payments — averaging $420.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$57K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$35K
  • Sun Pharmaceutical Industries Inc.$23K
  • Shire North American Group Inc$16K
  • Biotissue Holdings Inc.$13K
  • Kala Pharmaceuticals, Inc.$7K
  • plus $10K from 20 others
$21,750in research payments, 2019–2025

Across 1 payment — averaging $21,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch & Lomb Americas Inc.$22K

What the payments were for

  • Consulting fees$19,57512%
  • Speaking & faculty fees$115,70671%
  • Travel & lodging$16,42310%
  • Food & beverage$10,8167%
  • Education$2940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$162,814 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$593,789
Medicare patients
1,028
Services billed
5,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj34$959,546
RestasisCyclosporine147$130,993
Loteprednol Etabonate543$68,676
XiidraLifitegrast24$34,906
CequaCyclosporine15$17,554
LumiganBimatoprost24$14,006
MieboPerfluorohexyloctane/Pf18$13,460
RhopressaNetarsudil Mesylate24$13,347
Lotemax SmLoteprednol Etabonate51$12,905
VyzultaLatanoprostene Bunod23$12,351
TyrvayaVarenicline Tartrate16$11,308
ZirganGanciclovir20$9,431
Fluorometholone104$8,811
Cyclosporine20$8,354
SimbrinzaBrinzolamide/Brimonidine Tart36$7,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$57,334$959,54634 claims
AbbVieRestasis, Lumigan, Combigan$227$151,367190 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Prolensa, Lotemax$35,071$91,216624 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta, Zirgan$356$70,14885 claims
Sun Pharmaceutical Industries Inc.Cequa$23,457$17,55415 claims
Aerie Pharmaceuticals, Inc.Rhopressa$19$13,34724 claims
Oyster Point Pharma, Inc.Tyrvaya$2,936$11,30816 claims
AlconSimbrinza$224$7,36436 claims
Eyevance Pharmaceuticals LLCFlarex$1,772$3,08224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →